Page 6 - Pharmaceutical

Sun Pharma, Pharmazz enter agreement to introduce Sovateltide in India

Sun Pharma said in a filing that it has been granted rights for marketing Sovateltide in India under the brand name Tyvalzi

How India has been supplying quality drugs affordably to the entire world

With Indian innovation coming into its own and the Indian pharma industry ushering in a new wave of healthcare concepts, we will see India strengthening its position as the pharmacy to the world

Generic medicines: Indian pharma market is at crossroads of systemic shift

Companies must start preparing their business models to adjust to the reality of the shift to medical practitioners prescribing only generic molecule names

Cipla, Torrent may need to divest 15 brands in buyout deal: Bernstein

Torrent has a strong presence in gastrointestinal, neurology, and cardiac segments

EFTA looking at reduction in trade barriers on pharma in pact with India

Four-nation bloc EFTA is looking at significant reduction in trade barriers on sectors such as machine tools, advanced chemicals, pharma, chocolates, Norwegian and Icelandic fish in the proposed free trade agreement with India, a Swiss minister said. Swiss State Secretary for Economic Affairs Helene Budliger Artieda also said that with India, the EFTA grouping is aiming for an ambitious and comprehensive agreement in trade in goods, services and protection of intellectual property rights (IPRs). India and European Free Trade Association (EFTA) states Iceland, Liechtenstein, Norway, and Switzerland - are negotiating a Trade and Economic Partnership Agreement (TEPA) with a view to boosting economic ties between the two regions. Negotiations on the agreement were officially launched in January 2008. 13 rounds of negotiations were held until autumn 2013 before the talks were put on hold. After talks were resumed in October 2016, a number of rounds have taken place. Regarding trade in

Doctors to be penalised for not prescribing generic drugs: NMC regulation

All doctors must prescribe generic drugs, failing which they will be penalised and even their license to practice may also be suspended for a period, according to the new regulations issued by the National Medical Commission. The National Medical Commission (NMC) in its 'Regulations relating to Professional Conduct of Registered Medical Practitioners" also asked doctors to avoid prescribing branded generic drugs. Even though doctors are currently required to prescribe generic drugs only, there are no penal provisions mentioned in the regulations issued in 2002 by the Indian Medical Council. The NMC regulations notified on August 2, stated that India's out-of-pocket spending on medications accounts for a major proportion of public spending on healthcare. "Generic medicines are 30 to 80 per cent cheaper than branded drugs. Hence, prescribing generic medicines may overtly bring down healthcare costs and improve access to quality care," it said. Under the generic medicine and prescrip

Top headlines: SBI beats RIL, becomes most profitable firm, and more

Business Standard brings you the top headlines at this hour

Nirma emerges as frontrunner for Glenmark's API arm as bid deadline ends

Nirma Ltd and Sekhmet Pharmaventures were among the shortlisted bidders for a controlling stake in GLS

Revenue of top domestic pharmaceutical firms to grow by 7-9% in FY24: Icra

Revenue of top domestic pharmaceutical companies is likely to grow by 7-9 per cent in the current fiscal, according to rating agency Icra. The growth will be supported by an 8-10 per cent expansion in the domestic market and a 6-8 per cent rise in the US market, while revenues from the European and emerging markets are expected to increase by 3-5 per cent and 8-10 per cent, respectively, it noted. Icra said it has taken into account a sample set of 25 Indian drug firms, which constitute 60 per cent of the overall domestic industry. The segment reported a growth of 10 per cent in the 2022-23 fiscal. Icra said that a continued focus on complex generics/speciality launches in the US market is expected to support industry margins in FY2024. The overall credit profile of Indian pharmaceutical companies is expected to remain healthy, supported by their stable earnings profile, comfortable leverage and coverage metrics, and strong liquidity position, it added. "The 8-10 per cent growth

1 drug sample spurious and nearly 48 substandard in June inspection

Eye-drops made by Indiana Ophthalmics in Gujarat that have been under the scanner also feature in the list

Jubilant Pharmova's Q1 consolidated net profit dips 87% at Rs 6 cr

Jubilant Pharmova Ltd on Wednesday reported an 87 per cent decline in consolidated net profit at Rs 6 crore in the first quarter ended June 30, impacted by higher expenses. The company had posted a consolidated net profit of Rs 46.8 crore in the same period last fiscal, Jubilant Pharmova said in a regulatory filing. Consolidated total revenue from operations were at Rs 1,586.9 crore, as compared to Rs 1,451.7 crore in the year-ago period, it added. Total expenses in the first quarter were at Rs 1,568.9 crore, as compared to Rs 1,393.8 crore in the corresponding period a year ago. Among various segments, Jubilant Pharmova said the radiopharmaceuticals vertical clocked a revenue of Rs 204 crore in the first quarter, while the radiopharmacies registered Rs 487 crore revenue. The generics business had a revenue of Rs 202 crore and the contract development and manufacturing organisation (CDMO) API segment had posted revenue of Rs 177 crore.

NIPER JEE 2023 exam is set to be held on July 13, check full update below

NIPER JEE exam is set to be conducted on July 13. The exam will be held in a computer-based test mode, and candidates can download the admit cards from the official website niperguwahati.ac.in

Aurigene Pharmaceutical Services to set up $40 mn facility in Hyderabad

Aurigene Pharmaceutical Services Ltd will establish its state-of-the art biomanufacturing facility at an investment of USD 40 million here, which will generate employment to more than 250 people. Telangana Minister for IT and Industries KT Rama Rao in a tweet said Hyderabad offers an excellent ecosystem for biologics Research and Development with 30-40 per cent of total capacity for biologics in India. I'm happy to note that this investment has further bolstered Hyderabad's status as the top choice for biopharmaceutical research and production. I'm confident that we will continue to make significant strides in promoting "Complex manufacturing at scale," he said in the tweet. Aurigene Pharmaceutical Services is a city-based leading contract research, development, and manufacturing organization (CRO/CDMO) and a long-term partner providing end-to-end solutions thereby accelerating innovation.

Eli Lilly's 'triple G' anti-obesity drug leads to 24% weight loss in trial

The pharma company published the results of phase two of the clinical trial of Retatrutide, showing impressive weight loss and regulation of blood sugar levels in undertrials

Instead of cough syrup testing, need to go for root-cause analysis: Bhaskar

Pharmaceutical exports from India have come under the scanner after sporadic incidents of contaminated or substandard medicines

LIVE: UN Yoga Day celebration makes to Guinness World Record book

Catch all the live updates from across the globe here

Natco gets USFDA approval for Tipiracil Hydrochloride, Trifluridine Tablets

Shares of Natco Pharma Ltd, on Friday, fell over 1 per cent at Rs 632 on BSE

Need sectoral strategies to enhance export competitiveness: IIPMB Director

There is a need to develop sectoral strategies for enhancing export competitiveness, especially for electronics, engineering, pharmaceutical, and high-tech industries with a view to increase India's outbound shipments to USD 2 trillion by 2030, a trade expert said on Tuesday. To achieve the target of USD 2 trillion in services and goods exports by 2030, India requires an export growth of 14.5 per cent per annum. "Competitiveness across the exports value chain is the key to India's exports growth and its sustainability. In addition to generalised strategies, India needs to evolve sectoral strategies for export competitiveness, especially for engineering goods, pharmaceutical, electronics, and high-tech industries," Indian Institute of Plantation Management Bengaluru (IIPMB) Director Rakesh Mohan Joshi said. Sectors like polished diamonds, jewellery, passenger cars, telecommunication equipment would help in increasing the shipments. In terms of countries, tremendous unexplored potent

Dr Reddy's completes Phase-I study in proposed biosimilar of tocilizumab

Global Phase III study is being initiated to compare the efficacy, safety, tolerability and immunogenicity of DRL_TC with the reference product

From June 1, cough syrups must be tested at govt labs before export

Presently over 80% of the antiretroviral drugs used globally to combat AIDS are supplied by Indian pharmaceutical firms